Branford, CT (PRWEB) April 22, 2013
BioXcel Corporation, coinciding with the BIO International 2013 Convention in Chicago, announced the launch of PharmGPS™, a “first-in-class,” dynamic analytics platform with customizable apps, built to address complex investment decisions across the biopharmaceutical industry stakeholder value-chain.
“Decision making and knowledge management paradigms are fragmented and becoming increasingly complex with the explosion of data and a rapidly evolving healthcare ecosystem,” said Dr. Vimal Mehta, BioXcel’s Chairman. “PharmGPS™ provides an innovative solution to revolutionize decision making with a unified platform for actionable decisions thereby optimizing investments and enhancing the probability of success.
PharmGPS™ is a disease-area focused, analytics engine encompassing all major and specialty therapeutic areas. Using a patient-centric approach, PharmGPS™ assesses each disease indication for the best window of commercial opportunity, dynamic probability of technical and regulatory success, forecasting, and scenario analysis. This applies to both in-market and pipeline drugs, satisfying the future standard of care in each disease indication/segment. “BioXcel’s long-term commitment to developing PharmGPSTM has been supported by multiple clients working to meet patient needs,” said Dr. Krishnan Nandabalan, BioXcel’s President & CEO. “We are vigorously expanding current indications and commercializing this exciting new product to a wide biopharmaceutical audience.”
The platform is built on several years’ experience, deep domain expertise, commercially validated frameworks, and proprietary processes for generating insights and recommendations. The analytics engine operates on dynamic specialized data sets, each structured by experts from medical, clinical, scientific, commercial, and intellectual property disciplines. It also allows stakeholders to leverage intern
Copyright©2012 Vocus, Inc.
All rights reserved